METASTATIC BONE PAIN THERAPY
Currently this
procedure can be conducted using two radiopharmaceuticals. The first one to be
introduced was based on 89 Strontium as radionuclide and the second one
labelling the tracer with 153 Samarium.
More recently and still under phase III clinical research it is important to mention chloride 223 radium, an alpha emitter, with less hematological toxicity and which has been suggested to treat bone metastasis in prostatic carcinoma as well (1).
The properties and use of 89 Strontium and 153 Samarium EDTMP wil be discussed considering the following aspects.
References:
1 Liepe K.. Alpharadin,
a 223 Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone
metastases in patients with cancer. Curr Opin Investig Drugs. 2009
Dec;10(12):1346-58.